Cellectis Interview Guide

Cellectis is a pioneering biopharmaceutical company founded in 1999, dedicated to developing innovative immunotherapies through gene-edited CAR-T cells, specifically its UCART technology. With 17 years of expertise in gene editing, Cellectis leverages its flagship TALEN® products, meganucleases, and cutting-edge electroporation technology, PulseAgile, to revolutionize cancer treatment. The company's mission is to create a new generation of therapies that harness engineered T-cells to target surface antigens on various cells, aiming to transform patient outcomes across multiple therapeutic fields. As a publicly traded entity on the Nasdaq Global Market (ticker: CLLS) and the NYSE Alternext market (ticker: ALCLS), Cellectis is positioned at the forefront of the biotech industry, with a dedicated team ranging from 51 to 200 professionals committed to advancing the future of oncology.